Genmab’s plans after $500M NASDAQ debut

European bellwether Genmab plans to use a large chunk of the $505.9 million it raised through its listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC).

Two other companies began trading NASDAQ Thursday after pricing IPOs late Wednesday. Mirum and Fulcrum both fell in their first day of trading...